Last reviewed · How we verify
Detectnet (copper dotatate Cu-64)
Detectnet (generic name: copper dotatate Cu-64) is a Radioactive Diagnostic Agent [EPC] drug developed by Radiomedix. It is currently FDA-approved (first approved 2020) for Positron emission tomography.
Copper Cu 64 dotatate binds to somatostatin receptors, particularly SSTR2, on neuroendocrine tumor cells, allowing PET imaging.
Detectnet is being studied in clinical trials for the treatment of Neuroendocrine Tumors and Somatostatin Receptor-positive Neuroendocrine Tumor. The treatment involves the use of 64Cu-Dotatate, which is administered through imaging techniques such as Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) and Photon Emission Tomography / CT (PET/CT).
At a glance
| Generic name | copper dotatate Cu-64 |
|---|---|
| Sponsor | Radiomedix |
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Target | somatostatin receptors, particularly SSTR2 |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2020 |
Mechanism of action
Copper Cu 64 dotatate specifically targets and binds to somatostatin receptors, especially subtype 2 (SSTR2), which are overexpressed on certain neuroendocrine tumor cells. This binding enables the drug to be used in positron emission tomography (PET) imaging, helping to visualize these tumors.
Approved indications
- Positron emission tomography
Common side effects
- Nausea
- Vomiting
- Flushing
Serious adverse events
- Hypersensitivity reactions
- Rash
- Pruritus
- Angioedema
- Anaphylaxis
Key clinical trials
- Using Novel Imaging to More Safely Treat Neuroendocrine Tumors (PHASE1)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors. (PHASE1)
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs (PHASE2)
- Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors (PHASE4)
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (PHASE3)
- 64Cu-DOTATATE PET-CT-skanning and Infective Endocarditis. (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Detectnet CI brief — competitive landscape report
- Detectnet updates RSS · CI watch RSS
- Radiomedix portfolio CI
Frequently asked questions about Detectnet
What is Detectnet?
How does Detectnet work?
What is Detectnet used for?
Who makes Detectnet?
What is the generic name of Detectnet?
What drug class is Detectnet in?
When was Detectnet approved?
What development phase is Detectnet in?
What are the side effects of Detectnet?
What does Detectnet target?
Related
- Drug class: All Radioactive Diagnostic Agent [EPC] drugs
- Target: All drugs targeting somatostatin receptors, particularly SSTR2
- Manufacturer: Radiomedix — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Positron emission tomography
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing